奥氮平与齐拉西酮对女性首发精神分裂症患者的疗效及体重泌乳素的影响

Olanzapine and Ziprasidone Schizophrenia Curative Effect and Weight of Lactating Patients in the First-episode Female Spirit

目的:观察奥氮平与齐拉西酮治疗首发女性精神分裂症患者的疗效和对女性患者体重及泌乳素的影响。方法:将98例女性精神分裂症急性发作的患者随机分为奥氮平组(n=48)、齐拉西酮组(n=50),观察6周。在治疗前及治疗后第2、4、6周采用阳性和阴性症状量表评定疗效,并测量体重及进行实验室检查。结果:女性首发精神分裂症患者初次使用奥氮平、齐拉西酮治疗,总有效率分别为83.3%、78.00%,两组有效率和无效率比较,差异无统计学意义(χ2=0.16,P>0.05);奥氮平组PANSS总分的改善优于齐拉西酮组(P<0.05);治疗后,齐拉西酮组体重及泌乳素未见明显变化(P>0.05),奥氮平组体重及泌乳素显著增高(P<0.01);奥氮平组体重及泌乳素显著高于齐拉西酮组(P<0.01)。结论:齐拉西酮和奥氮平对首次接受治疗的女性精神分裂症患者均具有明确疗效,但奥氮平对患者症状的改善略优于齐拉西酮。与奥氮平相比,齐拉西酮对首次治疗的女性精神分裂症的体重及泌乳素几乎没有影响,相比较而言女性患者对齐拉西酮依从性要好。

Objective： To observe the effects of olanzapine and ziprasidone in the treatment of first-episode female schizophrenia patients and the female body weight and prolactir~ Methods： 98 patients of f^mle schizophrenia acute onset were divided into olanzapine group （n~ 48）, zipmsidone group （n~ 50）, were observed for 6 weeks. Before treatment and after treatment in 2,4, 6 weeks by positive and negative symptoms scale assessment of efficacy, and body weight measurement and laboratory examina- tion. Results. Female first-episode schizop~_nia patients with olanzapine,zipmsidone treatment, total effective rate was 83. 3%, 78~ ,two groups of efficiency comparison, no significant difference（yZ =0. 16, P^0. 05） ; ziprasidone group and olarmapine group was better than that of PANSS scores （P^0. 05）. After treatment,significant changes in body weight and prolactin in zipmsidone group and olanzapine group （P~ 0.05）, no weight and prolactin increased significantly （ P-（ 0. 01 ） ; olanmpine group weight and prolactin were significantly higher than that d zipmsidone group （P,C0. 01）. Conduslon. Zipmsidone and olanzapine on the first treatment of female schizophrmic patients have definite efficacy, but the improvement of symptoms in patients with olanzapine is slightly superior to ziprasidone. Compared with olanzapine, ziprasidone in the treatment of female schizophrenia for the first time, body weight and lactation in meat is almost no effect, compared with female patients of ziprasi- done compliance.